Zongbing You1, Dongxia Ge1, Sen Liu1, Qiuyang Zhang1, Alexander D Borowsky2, Jonathan Melamed3. 1. Department of Structural & Cellular Biology, Department of Orthopaedic Surgery, Tulane Cancer Center, Louisiana Cancer Research Consortium, Tulane Center for Stem Cell Research and Regenerative Medicine, Tulane Center for Aging, Tulane University School of Medicine, New Orleans, Louisiana 70112. 2. Department of Pathology & Laboratory Medicine and Center for Comparative Medicine, University of California Davis, Davis, California 95616. 3. Department of Pathology, New York University School of Medicine, New York, New York 10016.
Abstract
BACKGROUND: Interleukin-17 (IL-17A) expression is increased in prostate cancer. This study investigated the expression of IL-17A receptor C (IL-17RC) in prostatic intraepithelial neoplasia (PIN) lesions and the effects of IL-17A on prostatic epithelial cells in in-vitro studies. METHODS: IL-17RC expression in human and rodent prostate tissues was detected by immunohistochemistry. Quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) and Western blot analyses were used to determine mRNA and protein expression in human and mouse prostatic epithelial cell lines. RESULTS: IL-17RC protein was increased in human and rodent PIN lesions, compared to the normal human and rodent prostatic epithelium. IL-17A treatment activated the Nuclear Factor-κB (NF-κB) and/or Extracellular signal-Regulated Kinase (ERK) pathways in human PIN and LNCaP cell lines as well as mouse prostate cancer cell line TRAMP-C1. IL-17A treatment did not affect cell growth of the cell lines studied. However, IL-17A induced expression of CXCL1, CXCL2, CCL2, CCL5, and IL-6 in human and mouse prostatic epithelial cell lines. When the full-length IL-17RC was over-expressed in human PIN and LNCaP cell lines, activation of NF-κB and/or ERK pathways and expression of CXCL1, CXCL2, and CCL5 chemokines were significantly enhanced upon IL-17A treatment. CONCLUSION: These findings suggest that the prostatic epithelial cells in PIN lesions may respond to IL-17A stimuli with augmented synthesis of chemokines, due to increased IL-17RC expression.
BACKGROUND: Interleukin-17 (IL-17A) expression is increased in prostate cancer. This study investigated the expression of IL-17A receptor C (IL-17RC) in prostatic intraepithelial neoplasia (PIN) lesions and the effects of IL-17A on prostatic epithelial cells in in-vitro studies. METHODS:IL-17RC expression in human and rodent prostate tissues was detected by immunohistochemistry. Quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) and Western blot analyses were used to determine mRNA and protein expression in human and mouse prostatic epithelial cell lines. RESULTS:IL-17RC protein was increased in human and rodent PIN lesions, compared to the normal human and rodent prostatic epithelium. IL-17A treatment activated the Nuclear Factor-κB (NF-κB) and/or Extracellular signal-Regulated Kinase (ERK) pathways in human PIN and LNCaP cell lines as well as mouseprostate cancer cell line TRAMP-C1. IL-17A treatment did not affect cell growth of the cell lines studied. However, IL-17A induced expression of CXCL1, CXCL2, CCL2, CCL5, and IL-6 in human and mouse prostatic epithelial cell lines. When the full-length IL-17RC was over-expressed in human PIN and LNCaP cell lines, activation of NF-κB and/or ERK pathways and expression of CXCL1, CXCL2, and CCL5 chemokines were significantly enhanced upon IL-17A treatment. CONCLUSION: These findings suggest that the prostatic epithelial cells in PIN lesions may respond to IL-17A stimuli with augmented synthesis of chemokines, due to increased IL-17RC expression.
Authors: E Tartour; F Fossiez; I Joyeux; A Galinha; A Gey; E Claret; X Sastre-Garau; J Couturier; V Mosseri; V Vives; J Banchereau; W H Fridman; J Wijdenes; S Lebecque; C Sautès-Fridman Journal: Cancer Res Date: 1999-08-01 Impact factor: 12.701
Authors: Alexander D Borowsky; Karen H Dingley; Esther Ubick; Kenneth W Turteltaub; Robert D Cardiff; Ralph Devere-White Journal: Neoplasia Date: 2006-09 Impact factor: 5.715
Authors: Xin Li; Robert Loberg; Jinhui Liao; Chi Ying; Linda A Snyder; Kenneth J Pienta; Laurie K McCauley Journal: Cancer Res Date: 2009-01-27 Impact factor: 12.701
Authors: Georg E Steiner; Martin E Newman; Doris Paikl; Ursula Stix; Nima Memaran-Dagda; Chung Lee; Michael J Marberger Journal: Prostate Date: 2003-08-01 Impact factor: 4.104
Authors: Georg E Steiner; Ursula Stix; Alessandra Handisurya; Martin Willheim; Andrea Haitel; Franz Reithmayr; Doris Paikl; Rupert C Ecker; Kristian Hrachowitz; Gero Kramer; Chung Lee; Michael Marberger Journal: Lab Invest Date: 2003-08 Impact factor: 5.662
Authors: Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu Journal: Cancer Cell Date: 2003-09 Impact factor: 31.743
Authors: Sen Liu; Fengli Liu; Bing Zhang; Peng Yan; Brian G Rowan; Asim B Abdel-Mageed; Chad Steele; S Michal Jazwinski; Krzysztof Moroz; Elizabeth B Norton; Alun Wang; Leann Myers; Oliver Sartor; Qiuyang Zhang Journal: Prostate Date: 2020-05-01 Impact factor: 4.104
Authors: Petra Popovics; Andrew V Schally; Luis Salgueiro; Krisztina Kovacs; Ferenc G Rick Journal: Proc Natl Acad Sci U S A Date: 2017-01-25 Impact factor: 11.205
Authors: Marta Szyszka; Lukasz Paschke; Marianna Tyczewska; Karol Jopek; Piotr Celichowski; Paulina Milecka; Gulnara Sultanova; Ewelina Stelcer; Agnieszka Malinska; Ludwik K Malendowicz; Marcin Rucinski Journal: Int J Mol Sci Date: 2019-10-30 Impact factor: 5.923